The Obsolescence of Deciling in Biopharma Commercial Strategy
This analysis argues that the traditional biopharmaceutical commercial strategy of 'deciling'—sorting physicians into ten volume-based tiers to target high prescribers—is no longer effective in the current market. Originally designed for an era of blockbusters and stable customer bases, this backward-looking model fails to address modern complexities such as the rise of specialty drugs, health system consolidation, and shifting regulatory environments. Data indicates that deciling captures only about 60 percent of potential opportunities, leaving significant growth invisible because it ignores prescribing propensity and patient-specific needs. Furthermore, static segmentation causes competitors to converge on the same saturated high-decile physicians, resulting in diminishing returns on promotional investments. The article advocates for replacing static deciling with dynamic scoring models. These advanced approaches utilize real-time behavioral signals, engagement patterns, and patient population data to predict future growth rather than relying on historical prescription volumes. By adopting these dynamic methods, commercial teams can identify undervalued physicians with genuine potential, optimize resource allocation, and navigate the increased uncertainty of today's healthcare landscape with greater precision.
Wire timeline
The Obsolescence of Deciling in Biopharma Commercial Strategy
This analysis argues that the traditional biopharmaceutical commercial strategy of 'deciling'—sorting physicians into ten volume-based tiers to target high prescribers—is no longer effective in the current market. Originally designed for an era of blockbusters and stable customer bases, this backward-looking model fails to address modern complexities such as the rise of specialty drugs, health system consolidation, and shifting regulatory environments. Data indicates that deciling captures only about 60 percent of potential opportunities, leaving significant growth invisible because it ignores prescribing propensity and patient-specific needs. Furthermore, static segmentation causes competitors to converge on the same saturated high-decile physicians, resulting in diminishing returns on promotional investments. The article advocates for replacing static deciling with dynamic scoring models. These advanced approaches utilize real-time behavioral signals, engagement patterns, and patient population data to predict future growth rather than relying on historical prescription volumes. By adopting these dynamic methods, commercial teams can identify undervalued physicians with genuine potential, optimize resource allocation, and navigate the increased uncertainty of today's healthcare landscape with greater precision.
PharmExec articles